[HTML][HTML] Lung screening benefits and challenges: a review of the data and outline for implementation

J Sands, MC Tammemägi, S Couraud… - Journal of Thoracic …, 2021 - Elsevier
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for almost
a fifth of all cancer-related deaths. Annual computed tomographic lung cancer screening …

Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology

AKP Ganti, BW Loo, M Bassetti, C Blakely… - Journal of the National …, 2021 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …

Tarlatamab for patients with previously treated small-cell lung cancer

MJ Ahn, BC Cho, E Felip, I Korantzis… - … England Journal of …, 2023 - Mass Medical Soc
Background Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

J Trigo, V Subbiah, B Besse, V Moreno, R López… - The lancet …, 2020 - thelancet.com
Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …

NCCN guidelines insights: small cell lung cancer, version 2.2018

GP Kalemkerian, BW Loo, W Akerley, A Attia… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease
management. These NCCN Guidelines Insights focus on recent updates to the NCCN …

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

I Cañadas, R Thummalapalli, JW Kim, S Kitajima… - Nature medicine, 2018 - nature.com
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote
treatment resistance,,–. This phenomenon has been implicated in chemorefractory small cell …

NCCN guidelines® insights: lung cancer screening, version 1.2022: featured updates to the NCCN guidelines

DE Wood, EA Kazerooni, D Aberle, A Berman… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting
individuals for screening and provide recommendations for evaluation and follow-up of lung …

[HTML][HTML] PARP inhibitors in small-cell lung cancer: rational combinations to improve responses

EH Knelson, SA Patel, JM Sands - Cancers, 2021 - mdpi.com
Simple Summary Small-cell lung cancer carries a dismal prognosis with few long-term
treatment options. The enzyme poly-(ADP)-ribose polymerase (PARP), which functions to …

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer

S Patel, WJ Petty, JM Sands - Therapeutic Advances in …, 2021 - journals.sagepub.com
Small cell lung cancer (SCLC) is a highly proliferative, aggressive form of lung cancer that
carries a poor prognosis. Recent approvals with new therapeutic options represent the first …

Rates of guideline-concordant surgery and adjuvant chemotherapy among patients with early-stage lung cancer in the US ALCHEMIST study (Alliance A151216)

KL Kehl, D Zahrieh, P Yang, SL Hillman, AD Tan… - JAMA …, 2022 - jamanetwork.com
Importance Standard treatment for resectable non–small cell lung cancer (NSCLC) includes
anatomic resection with adequate lymph node dissection and adjuvant chemotherapy for …